Judgement laid down in important Warner-Lambert case

14 November 2018

Generic drugmakers Actavis and Mylan (Nasdaq: MYL) have prevailed in a patent dispute against Warner-Lambert, now part of the Pfizer (NSE: PFE) group of companies.

The UK case, which has provided a potentially important precedent for patent law surrounding claims of new medical uses for protected products, related to the blockbuster drug pregabalin, marketed by Warner-Lambert under the name Lyrica and authorized to treat neuropathic pain, generalised anxiety disorder (GAD) and epilepsy.

"The ruling will make patents easier to avoid and more vulnerable to invalidation"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK